The Role of Perirenal Fat As Predictor in Diabetic Nephropathy
1 other identifier
observational
100
0 countries
N/A
Brief Summary
1 detect the relationship between perirenal fat thickness (PrFT) and estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes (T2DM). 2)Explored the relationship between PRF thickness and the onset and progression of albuminuria in patients with diabetes 3)Evaluate associations between obesity-related markers with albuminuria and advanced kidney disease in patients with type 2 diabetes mellitus (DM)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 26, 2024
CompletedFirst Posted
Study publicly available on registry
February 7, 2025
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
February 7, 2025
February 1, 2025
1.8 years
May 26, 2024
February 3, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
the thickness of preirenal fat in diabetic patients
Follow up the patient with sonar to detect early changes in perirenal fat in diabetic patient. perirenal fat is the thickness of the fat capsule along the long axis of the kidney, and pararenal fat was the thickness of the fat layer measured between the medial surface of abdominal muscle tissue and the renal fascia.
Basaline
Interventions
Abdominal sonar
Eligibility Criteria
Follow up patient is T2DM
You may qualify if:
- \- Patients with T2DM aged 18-70 were included in this study. T2DM was diagnosed according to American Diabetes Association (ADA) ,Data collection will obtained over one year from October 2024 to October 2025.
- Clinical diagnosis of Alzheimer's Disease Must be able to swallow tablets
You may not qualify if:
- patients with a history of malignancy and surgical trauma.
- patients diagnosed with nondiabetic renal diseases
- Patients with renal replacement therapy (renal transplant or dialysis patients), renal morphological abnormalities (difference in kidney length between the two cm, solitary kidney or multiple kidneys, congenital kidney abnormalities, polycystic kidney, and hydronephrosis), liver cirrhosis.
- Insulin dependent diabetes
- Thyroid disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Nephrology Resident
Study Record Dates
First Submitted
May 26, 2024
First Posted
February 7, 2025
Study Start
March 1, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
February 7, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share